Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Christopher Foley

Showing results (21-30 of 36) with videos related to

Pageof 4
Sort By:
Aging Cell|August 6, 2017
Dyrk1 inhibition improves Alzheimer's disease-like pathologyCaterina Branca, Darren M Shaw, Ramona Belfiore, et al.
Medrxiv : the Preprint Server for Health Sciences|August 21, 2020
Salivary anti-SARS-CoV-2 IgA as an accessible biomarker of mucosal immunity against COVID-19Atul Varadhachary, Dev Chatterjee, Javier Garza, et al.
Molecular Endocrinology (Baltimore, Md.)|June 13, 2015
miR-137 Targets p160 Steroid Receptor Coactivators SRC1, SRC2, and SRC3 and Inhibits Cell ProliferationVijay Kumar Eedunuri, Kimal Rajapakshe, Warren Fiskus, et al.
Environmental Health Perspectives|October 25, 2011
Opposing effects of particle pollution, ozone, and ambient temperature on arterial blood pressureBarbara Hoffmann, Heike Luttmann-Gibson, Allison Cohen, et al.
Cancer Research|October 3, 2014
Androgen receptor is the key transcriptional mediator of the tumor suppressor SPOP in prostate cancerChuandong Geng, Kimal Rajapakshe, Shrijal S Shah, et al.
Medrxiv : the Preprint Server for Health Sciences|September 5, 2025
Proteomic prediction of disease largely reflects environmental risk exposureKristin Tsuo, M Austin Argentieri, Danni Gadd, et al.
Journal of Medicinal Chemistry|September 30, 2024
Discovery and Functional Characterization of a Potent, Selective, and Metabolically Stable PROTAC of the Protein Kinases DYRK1A and DYRK1BGerrit Wilms, Kevin Schofield, Shayna Maddern, et al.
Endocrine-Related Cancer|October 12, 2021
Inhibition of GATA2 in prostate cancer by a clinically available small moleculeSalma Kaochar, Aleksandra Rusin, Christopher Foley, et al.
Plos Medicine|June 28, 2017
Low-intensity cognitive-behaviour therapy interventions for obsessive-compulsive disorder compared to waiting list for therapist-led cognitive-behaviour therapy: 3-arm randomised controlled trial of clinical effectivenessKarina Lovell, Peter Bower, Judith Gellatly, et al.
Health Technology Assessment (Winchester, England)|July 7, 2017
Clinical effectiveness, cost-effectiveness and acceptability of low-intensity interventions in the management of obsessive-compulsive disorder: the Obsessive-Compulsive Treatment Efficacy randomised controlled Trial (OCTET)Karina Lovell, Peter Bower, Judith Gellatly, et al.
Pageof 4

Showing results (21-30 of 36) with videos related to

Sort By:
Pageof 4
Aging Cell|August 6, 2017
Dyrk1 inhibition improves Alzheimer's disease-like pathologyCaterina Branca, Darren M Shaw, Ramona Belfiore, et al.
Medrxiv : the Preprint Server for Health Sciences|August 21, 2020
Salivary anti-SARS-CoV-2 IgA as an accessible biomarker of mucosal immunity against COVID-19Atul Varadhachary, Dev Chatterjee, Javier Garza, et al.
Molecular Endocrinology (Baltimore, Md.)|June 13, 2015
miR-137 Targets p160 Steroid Receptor Coactivators SRC1, SRC2, and SRC3 and Inhibits Cell ProliferationVijay Kumar Eedunuri, Kimal Rajapakshe, Warren Fiskus, et al.
Environmental Health Perspectives|October 25, 2011
Opposing effects of particle pollution, ozone, and ambient temperature on arterial blood pressureBarbara Hoffmann, Heike Luttmann-Gibson, Allison Cohen, et al.
Cancer Research|October 3, 2014
Androgen receptor is the key transcriptional mediator of the tumor suppressor SPOP in prostate cancerChuandong Geng, Kimal Rajapakshe, Shrijal S Shah, et al.
Medrxiv : the Preprint Server for Health Sciences|September 5, 2025
Proteomic prediction of disease largely reflects environmental risk exposureKristin Tsuo, M Austin Argentieri, Danni Gadd, et al.
Journal of Medicinal Chemistry|September 30, 2024
Discovery and Functional Characterization of a Potent, Selective, and Metabolically Stable PROTAC of the Protein Kinases DYRK1A and DYRK1BGerrit Wilms, Kevin Schofield, Shayna Maddern, et al.
Endocrine-Related Cancer|October 12, 2021
Inhibition of GATA2 in prostate cancer by a clinically available small moleculeSalma Kaochar, Aleksandra Rusin, Christopher Foley, et al.
Plos Medicine|June 28, 2017
Low-intensity cognitive-behaviour therapy interventions for obsessive-compulsive disorder compared to waiting list for therapist-led cognitive-behaviour therapy: 3-arm randomised controlled trial of clinical effectivenessKarina Lovell, Peter Bower, Judith Gellatly, et al.
Health Technology Assessment (Winchester, England)|July 7, 2017
Clinical effectiveness, cost-effectiveness and acceptability of low-intensity interventions in the management of obsessive-compulsive disorder: the Obsessive-Compulsive Treatment Efficacy randomised controlled Trial (OCTET)Karina Lovell, Peter Bower, Judith Gellatly, et al.
Pageof 4